HSNOHbio is advancing an early-stage research pipeline focused on selective modulation of the GluA3 AMPA receptor.
Target: GluA3 AMPA Receptor
Modality: Small-Molecule Allosteric Modulator
Proposed Mechanism: Positive Allosteric Modulation (PAM)
Development Stage: Computational Discovery / Preclinical Research Planning
Potential Therapeutic Areas:
Alzheimer's disease-related cognitive impairment
Schizophrenia
Depression
Autism spectrum disorder
Other neurological and psychiatric conditions
These therapeutic applications remain exploratory and have not been clinically validated.
Stage 1 — Molecular Design
Computational candidate identification, structural modeling, molecular docking, and preliminary drug-like property assessment.
Stage 2 — Chemical Synthesis
Synthesis and analytical characterization of prioritized lead compounds.
Stage 3 — Target Validation
Evaluation of binding interactions and receptor subtype selectivity across GluA1, GluA2, GluA3, and GluA4.
Stage 4 — Functional Validation
Electrophysiological studies to determine receptor modulation, including patch-clamp experiments.
Stage 5 — Preclinical Development
Pharmacokinetics, blood-brain barrier penetration, safety assessment, and disease-relevant animal studies.
Stage 6 — Clinical Development
Potential IND-enabling studies and clinical development, subject to successful preclinical validation, financing, and regulatory requirements.
To establish a differentiated CNS therapeutic pipeline based on selective receptor modulation and precision molecular engineering.